FDA Approves New Lengths for BD's Lutonix 018 DCB Product Line

 

June 3, 2019—BD (Becton, Dickinson and Company) announced that the FDA has approved expanded sizes of the company's Lutonix 018 drug-coated balloon (DCB) to treat long superficial femoral artery lesions in patients with peripheral artery disease. The new lengths are 80, 100, 150, and 220 mm.

According to the company, the Lutonix 018 DCB's variety of longer sizes allow more options for treating 7-mm-diameter vessels. The device is designed to perform over small guidewires, reduce guidewire exchanges, and enable alternative access sites.

Lutonix 018 DCB is available in the United States and currently undergoing the regulatory approval process in Europe, stated BD.

 

Contact Info

For advertising rates and opportunities, contact:
Craig McChesney
484-581-1816
cmcchesney@bmctoday.com

Stephen Hoerst
484-581-1817
shoerst@bmctoday.com

Charles Philip
484-581-1873
cphillip@bmctoday.com

About Endovascular Today

Endovascular Today is a publication dedicated to bringing you comprehensive coverage of all the latest technology, techniques, and developments in the endovascular field. Our Editorial Advisory Board is composed of the top endovascular specialists, including interventional cardiologists, interventional radiologists, vascular surgeons, neurologists, and vascular medicine practitioners, and our publication is read by an audience of more than 22,000 members of the endovascular community.